Skip to main content

Home/ Dr. Goodyear/ Group items tagged naltrexone

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor path... - 0 views

ebm.rsmjournals.com/...1036.full

low dose naltrexone LND low dose naltrexone cancer cell proliferation opioid growth factor OGF

shared by Nathan Goodyear on 27 Nov 12 - No Cached
  • Nathan Goodyear on 27 Nov 12
     
    low-dose naltrexone (NLD) is shown to inhibit growth in vivo.  This is important as it has implications in cancer therapies.  This study found a greater benefit with LDN and exogenous opioid growth factor (OGF).
Nathan Goodyear

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic... - 0 views

www.ncbi.nlm.nih.gov/...PMC3962576

microglia LDN low dose naltrexone pain inflammation

shared by Nathan Goodyear on 05 Jul 17 - No Cached
  • orally active competitive opioid receptor antagonist
  • 4.5 mg, though the dosage can vary a few milligrams below or above that common value
  • At the low dosage level, naltrexone exhibits paradoxical properties, including analgesia and anti-inflammatory actions
  • ...10 more annotations...
  • LDN may be an effective treatment for FM
  • In addition to the antagonist effect on mu-opioid and other opioid receptors, naltrexone simultaneously has an antagonist effect on non-opioid receptors (Toll-like receptor 4 or TLR4) that are found on macrophages such as microglia
  • It is via the non-opioid antagonist path that LDN is thought to exert its anti-inflammatory effects
  • Once activated, microglia produce inflammatory and excitatory factors that can cause sickness behaviors such as pain sensitivity, fatigue, cognitive disruption, sleep disorders, mood disorders, and general malaise
  • The neuroprotective action appears to result when microglia activation in the brain and spinal cord is inhibited
  • By suppressing microglia activation, naloxone reduces the production of reactive oxygen species and other potentially neuroexcitatory and neurotoxic chemicals
  • suppressed TNF-alpha, IL-6, MCP-1, and other inflammatory agents in peripheral macrophages
  • individuals with greater ESR at baseline experienced a greater drop in pain when taking LDN
  • LDN has been reported to reduce not only self-reported pain in that condition but also objective markers of inflammation and disease severity
  • Naltrexone has also shown some promise in improving disease severity in multiple sclerosis
  • Nathan Goodyear on 05 Jul 17
     
    LDN maybe useful in treating chronic pain via anti-inflammatory effects on microglia.
Nathan Goodyear

Low-Dose Naltrexone Reduces the Symptoms of Fibromyalgia - Stanford Systems Neuroscienc... - 0 views

snapl.stanford.edu/...ldn.html

low dose naltrexone LND pain inflammation fibromyalgia stanford

shared by Nathan Goodyear on 27 Nov 12 - No Cached
  • Nathan Goodyear on 27 Nov 12
     
    low dose naltrexone shown to reduce pain in those with fibromyalgia.  This is a very small study, though with positive results.
Nathan Goodyear

http://www.ldnresearchtrust.org/sites/default/files/LDN_Cancer.pdf - 0 views

www.ldnresearchtrust.org/...LDN_Cancer.pdf

cancer LDN low dose naltrexone naltrexone vitamin D vitamin D

shared by Nathan Goodyear on 01 Oct 14 - No Cached
  • Nathan Goodyear on 01 Oct 14
     
    low dose naltrexone plus vitamin D3 to treat cancer
Nathan Goodyear

Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and Asso... - 0 views

www.jpain.org/...abstract

naltrexone pain control

shared by Nathan Goodyear on 19 May 11 - No Cached
  • The antihyperalgesic and antiallodynic effects of oxycodone plus ultra-low-dose NTX (Oxytrex, Pain Therapeutics, Inc., San Mateo, CA) suggest a promising new treatment for neuropathic pain.
  • Nathan Goodyear on 19 May 11
     
    low dose naltrexone plus opiate therapy improves neuropathic pain
Nathan Goodyear

Oxytrex Minimizes Physical Dependence While Providing Effective Analgesia: A Randomized... - 0 views

www.jpain.org/...abstract

naltrexone pain control opiates

shared by Nathan Goodyear on 19 May 11 - No Cached
  • Active treatment groups attained comparable analgesia despite significantly lower drug use
  • preclinical data also show a suppression of opioid tolerance and dependence
  • Previous clinical data have shown ultralow-dose naltrexone enhances and prolongs oxycodone analgesia,
  • ...1 more annotation...
  • A cellular mechanism of action has been demonstrated to be the prevention of aberrant G protein signaling by mu opioid receptors caused by chronic opioid administration
  • Nathan Goodyear on 19 May 11
     
    low dose naltrexone improves pain control and reduced opioid addiction
Nathan Goodyear

Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study - Younger - 200... - 0 views

onlinelibrary.wiley.com/...full

naltrexone pain

shared by Nathan Goodyear on 19 May 11 - No Cached
  • Nathan Goodyear on 19 May 11
     
    small pilot study finds naltrexone reduces pain in patients with Fibromyalgia
Nathan Goodyear

Low-dose naltrexone (LDN): Tricking the body to heal itself - 0 views

www.sciencedaily.com/...110902133047.htm

low dose naltrexone LND opioid growth factor OGF inflammation cancer low dose naltrexone opioid growth factor

shared by Nathan Goodyear on 27 Nov 12 - No Cached
  • Nathan Goodyear on 27 Nov 12
     
    synopsis of a previously posted article on LDN and OGF in the potential use in cancer.
Nathan Goodyear

Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial - 0 views

www.ncbi.nlm.nih.gov/...PMC2657183

LDN low dose naltrexone naltrexone opiates opioids

shared by Nathan Goodyear on 20 Dec 16 - No Cached
  • Nathan Goodyear on 20 Dec 16
     
    LDN found to help reduce opiod withdrawal symptoms.
Nathan Goodyear

http://www.integratedhealthclinic.com/assets/byCancerType/Pancreatic/4-LDN%20and%20IV%2... - 0 views

www.integratedhealthclinic.com/...IV%20Alpha%20Lipoic%20Acid.pdf

alpha lipoic acid ALA cancer pancreatic LDN low dose naltrexone selenium milk thistle silymarin IV intravenous

shared by Nathan Goodyear on 10 Feb 14 - No Cached
  • Nathan Goodyear on 10 Feb 14
     
    Author describes the long-term survival of a man with metastatic pancreatic cancer using IV alpha lipoic acid, low dose naltrexone, diet, and oral triple therapy of milk thistle, ALA, and selenium.  The safety profile is very good as compared to traditional therapy for metastatic pancreatic cancer.
Nathan Goodyear

Naloxone inhibits immune cell function by suppressing superoxide production through a d... - 0 views

www.biomedcentral.com/...1742-2094-9-32.pdf

LDN low dose naltrexone immune system autoimmune disease inflammation superoxide

shared by Nathan Goodyear on 31 Jul 13 - No Cached
  • Nathan Goodyear on 31 Jul 13
     
    Low dose naltrexone is immune modulator. This study proposes the biochemistry of immune cell suppression through superoxide inhibition.
Nathan Goodyear

Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) Protocol for People ... - 0 views

ict.sagepub.com/...416.short

alpha lipoic acid IV intravenous ALA pancreatic cancer cancer LDN low dose naltrexone

shared by Nathan Goodyear on 08 Sep 14 - No Cached
  • Nathan Goodyear on 08 Sep 14
     
    Case study of 3 patients with Pancreatic cancer treated with IV alpha lipoic acid and LDN therapy.  This is a f/u to a patient treated and still living--case study published in '06.  Only, the abstract is currently available to the general public.  
Nathan Goodyear

Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor path... - 0 views

ebm.sagepub.com/...1036.short

LDN low dose naltrexone opioid growth factor cancer

shared by Nathan Goodyear on 08 Sep 14 - No Cached
  • Nathan Goodyear on 08 Sep 14
     
    LDN inhibits cell proliferation through increased opioid growth factor and receptor translation.
Nathan Goodyear

Revisiting the ALA/N (a-Lipoic Acid/Low- Dose Naltrexone) Protocol for People With Meta... - 0 views

journals.sagepub.com/...1534735409352082

low dose naltrexone pancreatic cancer alpha lipoic acid ALA LDN

shared by Nathan Goodyear on 02 Jul 19 - No Cached
  • Nathan Goodyear on 02 Jul 19
     
    3 case studies of the use of ALA and LDN to treat pancreatic cancer.
Nathan Goodyear

Revisiting the ALA/N (a-Lipoic Acid/Low- Dose Naltrexone) Protocol for People With Meta... - 0 views

low dose naltrexone LDN cancer pancreatic cancer alpha lipoic acid

shared by Nathan Goodyear on 01 Jul 19 - No Cached
  • Nathan Goodyear on 01 Jul 19
     
    3 case studies on the benefit of IV ALA and po LDN in the treatment of pancreatic cancer.
Nathan Goodyear

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization - 0 views

www.ncbi.nlm.nih.gov/...PMC6313374

LDN low dose naltrexone

shared by Nathan Goodyear on 02 Mar 21 - No Cached
  • Nathan Goodyear on 02 Mar 21
     
    Good review article of LDN and its effects.
Nathan Goodyear

Low-Dose Naltrexone in Combination with High-Dose Vitamin C in Cancer Patients: Our Exp... - 0 views

LDN metastasis IV vitamin C vitamin C cancer High dose IV vitamin C dose high dose vitamin C low naltrexone)

shared by Nathan Goodyear on 09 Mar 21 - No Cached
  • Nathan Goodyear on 09 Mar 21
     
    Review of one clinics experience with HDIVC and LDN.
Nathan Goodyear

Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperin... - 0 views

pubmed.ncbi.nlm.nih.gov/32943552

insulin resistance low dose naltrexone hyperinsulinemia insulin cancer LDN

shared by Nathan Goodyear on 10 Jan 21 - No Cached
  • Nathan Goodyear on 10 Jan 21
     
    LDN reverses, or rescues, inflammation driven insulin resistance hyperinsulinemia.
1 - 20 of 30 Next ›
Showing 20▼ items per page